Efficacy and Safety of Triple-targeted Drug Therapy in Treatment-naive Patients With Non-low-risk PAH: A Real-world, Multicenter Study

NCT06753981 · tracked via the Priya Life Science China tracker

Sponsor

Qianfoshan Hospital

Phase

Observational

Started

2024-12-10

Last updated

2024-12-31

Condition(s) studied

Arterial Pulmonary Hypertension (PAH)

Investigational drug(s) / intervention(s)

Endothelin receptor antagonist (ERA) combined with PDE5i/sGC agonist dual therapy prostacyclin drugs

Endothelin receptor antagonist (ERA) combined with PDE5i/sGC agonist dual therapy prostacyclin drugs: Endothelin receptor antagonist (ERA) combined with PDE5i/sGC agonist dual therapy prostacyclin drugs Including macitentan sildenafil/tadalafil or riociguat selexipag/epoprostenol.

Study summary

This study is a multicenter, prospective, observational study aimed at investigating the efficacy and safety of triple targeted drug therapy in patients with arterial pulmonary hypertension (PAH) who are not at low risk and are receiving initial treatment. The prognosis of arterial pulmonary hypertension is explored.

Eligibility

Sex

ALL

Min age

18 Years

Max age

80 Years

Healthy volunteers

Inclusion Criteria: * Consent and sign the informed consent form * Non-low-risk PAH treatment-naive patients Exclusion Criteria: * Positive acute vascular response test for idiopathic/hereditary/drug-related arterial pulmonary hypertension * Pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis (PVOD/PCH) with arterial pulmonary * Pregnant or lactating women * Suffering from mental illness or cognitive impairment * PAH patients with concurrent malignant tumors * Patients with moderate to severe hepatic impairment, renal impairment, and severe anemia * Currently participating in other interventional clinical studies * Key clinical data is incomplete, or the investigator considers that the patient has other factors that make them unsuitable for this study.

Primary outcome measure(s)

Pulmonary Vascular Resistance (PVR) — Up to 3 months

Trial sites (1)

Facility	City	Region	Status
Department of Respiratory, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, #16766, Jingshi Road, Jinan City, Shandong Province, China	Jinan	Shandong	Recruiting

More Qianfoshan Hospital trials in China

The Study of INTRA Spine Non Fusion Technique in the Treatment of Lumbar Degenerative Disease Enrolling by invitation

ZR001 Chemogenetics Gene Therapy Study in Patients With Parkinson's Disease Starting soon

Deep Learning Model and Risk Factors for Tacrolimus-related Acute Kidney Injury Active, not recruiting

Patient's Whole Process Follow-up Management(HOPE-1) Recruiting

ML-Based ABPA Recurrence Prediction and Clinical Utility Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06753981 on ClinicalTrials.gov ↗ ← All trials in China